Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 750-758

  Millward, M J ^a   Zalcberg, J ^a   Bishop, J F ^a   Webster, L K ^a   Zimet, A ^a   Rischin, D ^a   Toner, G C ^a   Laird, J ^a   Cosolo, W ^a   Urch, M ^a   Bruno, R ^a   Loret, C ^a   James, R ^a   Blanc, C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAUNDICE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031026743     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.750     Document Type: Article

References (39)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients. BMJ 311:899-909, 1995
2. Kris M, Cohen E, Gralla R: An analysis of 134 phase II trials in non-small cell lung cancer (NSCLC). Lung Cancer 2:119, 1986 (abstr)
3. Ettinger DS: Ifosfamide in the treatment of non-small cell lung cancer. Semin Oncol 16:31-38, 1989 (suppl 3)
4. Depierre A, Lemarie E, Dabouis G, et al.: A phase II study of navelbine (vinorelbine) in the treatment of non small cell lung cancer. Am J Clin Oncol 14:115-119, 1991
5. Bissery M, Guernard D, Gueritte-Voegelin F, et al.: Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
6. Extra J-M, Rousseau F, Bruno R, et al.: Phase I and pharmacokinetic study of Taxotere (RP56976, NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
7. Aapro MS, Zulian G, Alberto P, et al.: Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation of Taxotere. Ann Oncol 3:53, 1992 (suppl 5, abstr 208)
8. Burris H, Irvin R, Kuhn J, et al.: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
9. Pazdur R, Newman RA, Newman B, et al.: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1788, 1992
10. Bissett D, Setanoians A, Cassidy J, et al.: Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
11. Tomiak E, Piccart MJ, Kerger J, et al.: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994
12. Francis PA, Rigas JR, Kris MG, et al.: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
13. Fossella FV, Lee JS, Murphy WK, et al.: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
14. Cerny T, Kaplan S, Pavlidis N, et al.: Taxotere is an active drug in non small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387, 1994
15. 2 dose of docetaxel given with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
16. Fossella FV, Lee JS, Shin DM, et al.: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
17. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47:207-214, 1981
18. Verweij J, Planting ASTh, van den Berg MEL, et al.: A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors. Proc Am Soc Clin Oncol 13:148, 1994 (abstr 386)
19. Verweij J, Planting ASTh, van den Berg MEL, et al.: A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors. Ann Oncol 5:180, 1994 (suppl 8, abstr 910)
20. Verginol JC, Bruno R, Montay G, Frydman A: Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278, 1992
21. Olver IN, Webster LK, Millward MJ, et al.: A phase I and pharmacokinetic study of prolonged ambulatory infusion carboplatin. Cancer Chemother Pharmacol 37:79-85, 1995
22. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of Taxotere, in Workman P, Graham MA (eds): Pharmacokinetics and Cancer Chemotherapy. New York, NY, Cold Spring Harbor Laboratory, 1993, pp 305-313
23. Gullo JJ, Litterst CL, Maguire PJ, et al.: Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a 1 hour or as a 20 hour infusion. Cancer Chemother Pharmacol 5:21-26, 1980
24. Reece PA, Stafford I, Russell J, et al.: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304-309, 1987
25. Himmelstein KJ, Patton TF, Bett RJ, et al.: Clinical kinetics of cisplatin and some related species. Clin Pharmacol Ther 29:658-664, 1981
26. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
27. Von Hoff DD, Schilsky R, Reichert CM, et al.: Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 63:1527-1531, 1979
28. Schamberger RC, Weinstein HJ, Marcia JD, et al.: The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57:603-609, 1986
29. Keiden RD, Fanning J, Gatenby RA, et al.: Recurrent typhlitis, a disease resulting from aggressive chemotherapy. Dis Colon Rectum 32:206-209, 1989
30. Pestalozzi BC, Sotos GA, Choyke PL, et al.: Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71:1797-1800, 1993
31. Merine DS, Fishman EK, Jones B, et al.: Right lower quadrant pain in the immunocompromised patient: CT findings in 10 cases. Am J Roentgenol 149:1177-1179, 1987
32. Navari R, Madajewicz S, Anderson N, et al.: Oral ondansetron effectively controls cisplatin-induced delayed emesis. Proc Am Soc Clin Oncol 14:523, 1995 (abstr 1720)
33. Roila F, De Angelis V, Cognetti F, et al.: Ondansetron vs granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis. Proc Am Soc Clin Oncol 14:523, 1995 (abstr 1721)
34. Schellens JHM, Ma J, Bruno R, et al.: Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence taxotere/cisplatin and cisplatin/taxotere. Proc Am Soc Clin Oncol 13:132, 1994 (abstr 323)
35. Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1702, 1991
36. Schellens JHM, Ma J, Planting AST, et al.: Docetaxel (Taxotere) inhibits DNA-adduct formation and intracellular accumulation of cisplatin in human WBC but not in tumor cell lines. Proc Am Assoc Cancer Res 35:212, 1994 (abstr 1264)
37. Bruno R, Hille D, Thomas L, Riva A, et al.: Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in phase II studies. Proc Am Soc Clin Oncol 14:457, 1995 (abstr 1471)
38. Cole JT, Gralla RJ, Marques CB, et al.: Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:357, 1995 (abstr 1087)
39. Le Chevalier T, Belli L, Monnier A, et al.: Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): An interim analysis. Proc Am Soc Clin Oncol 14:350, 1995 (abstr 1059)